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Abstract
Background: Resveratrol, a naturally occurring phytopolyphenol compound, has attracted extensive interest in recent years
because of its diverse pharmacological characteristics. Although resveratrol possesses chemopreventive properties against
several cancers, the molecular mechanisms by which it inhibits cell growth and induces apoptosis have not been clearly
understood. The present study was carried out to examine whether PI3K/AKT/FOXO pathway mediates the biological effects
of resveratrol.
Methodology/Principal Findings: Resveratrol inhibited the phosphorylation of PI3K, AKT and mTOR. Resveratrol, PI3K
inhibitors (LY294002 and Wortmannin) and AKT inhibitor alone slightly induced apoptosis in LNCaP cells. These inhibitors
further enhanced the apoptosis-inducing potential of resveratrol. Overexpression of wild-type PTEN slightly induced
apoptosis. Wild type PTEN and PTEN-G129E enhanced resveratrol-induced apoptosis, whereas PTEN-G129R had no effect on
proapoptotic effects of resveratrol. Furthermore, apoptosis-inducing potential of resveratrol was enhanced by dominant
negative AKT, and inhibited by wild-type AKT and constitutively active AKT. Resveratrol has no effect on the expression of
FKHR, FKHRL1 and AFX genes. The inhibition of FOXO phosphorylation by resveratrol resulted in its nuclear translocation,
DNA binding and transcriptional activity. The inhibition of PI3K/AKT pathway induced FOXO transcriptional activity resulting
in induction of Bim, TRAIL, p27
/KIP1, DR4 and DR5, and inhibition of cyclin D1. Similarly, resveratrol-induced FOXO
transcriptional activity was further enhanced when activation of PI3K/AKT pathway was blocked. Over-expression of
phosphorylation deficient mutants of FOXO proteins (FOXO1-TM, FOXO3A-TM and FOXO4-TM) induced FOXO
transcriptional activity, which was further enhanced by resveratrol. Inhibition of FOXO transcription factors by shRNA
blocked resveratrol-induced upregulation of Bim, TRAIL, DR4, DR5, p27
/KIP1 and apoptosis, and inhibition of cyclin D1 by
resveratrol.
Conclusion/Significance: These data suggest that FOXO transcription factors mediate anti-proliferative and pro-apoptotic
effects of resveratrol, in part due to activation of extrinsic apoptosis pathway.
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Introduction
Prostate cancer, one of the more common neoplasms in the
western world, arises through the progressive development of one
or more pre neoplastic lesions into adenocarcinoma, and
subsequently to metastatic disease [1]. Recent advances have
identified key genetic alterations that can initiate prostate
carcinogenesis, and enhance the probability of cancer progression.
Prostate cancer cells are only modestly responsive or even
unresponsive to the cytotoxic effects of chemotherapeutic agents
or radiotherapy. Increased concentrations of cytotoxic drugs and
higher dosages of irradiation fail to improve the response to
therapy and it leads to resistance to apoptosis in prostate cancer
cells. Thus, it is imperative to identify anticancer agents that are
nontoxic and highly effective in inducing apoptosis preferentially
in tumor cells.
Epidemiological data support the concept that naturally
occurring compounds in the human diet may be devoid of toxicity
and have long lasting beneficial effects on human health.
Resveratrol has been shown to exhibit several potential chemopro-
tective activities in cell and animal models [2,3,4,5,6,7,8,9],
including inhibition of PI3K/AKT pathway [2,6,8,10]. We have
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tial of TRAIL by upregulating death receptors (TRAIL/DR4 and
TRAIL-R2/DR5) and also engaging mitochondrial pathway of
apoptosis [2,3]. Deletion or mutation of PTEN has been the main
cause for constitutively active AKT leading to prostate carcinogen-
esis in humans [11,12]. Thus, resveratrol may be potential
candidate to target cells with PTEN deletion or inactivation and
enhanced AKT activity in precancerous prostate tissue.
PI3K signaling plays a pivotal role in intracellular signal
transduction pathways involved in cellular transformation, cell
growth, and tumorigenesis. Inactivation of AKT results in
dephosphorylation and activation of FOXO transcription factors,
reported to mediate cell cycle arrest, DNA repair, and apoptosis
[13,14]. These transcription factors, belong to the ‘O’ subgroup of
winged-helix/forkhead transcription-factor family, consist princi-
pally of four members FOXO1, FOXO3a, FOXO4, and FOXO6
[15]. FOXO proteins are evolutionarily conserved transcription
factors implicated in several fundamental cellular processes,
functioning as end-point for transcriptional programs involved in
apoptosis, stress response and longevity [16,17,18,19,20]. Abro-
gation of FOXO function is frequently observed in human cancer
[17,21], therefore the mechanisms of regulation of the FOXO
proteins are receiving increasing attention in cancer research. The
FOXO proteins integrate regulatory inputs from a variety of
upstream signaling pathways, most importantly in response to
growth factor and stress signaling [17,21]. Recently, FOXO
factors have been established as tumor suppressors, promoting the
transcription of pro-apoptotic molecules like FasL and Bim when
the PI3K/AKT pathway is downregulated due to nutrient or
serum starvation and cellular stress [22,23,24]. Triple knockout
mouse models proved the tumor suppressor properties of FOXOs,
as mice simultaneously lacking the principal members of the
mammalian FOXO subfamily, FOXO1, FOXO3a and FOXO4,
are prone to develop hemangiomas and lymphoproliferative
diseases [25]. Conversely, the individual or paired inactivation of
FOXO1, FOXO3a or FOXO4 resulted in a less severe
phenotype, supporting the idea of functional redundancy of these
FOXO factors [25]. Furthermore, forced expression of FOXO has
been shown to inhibit tumorigenesis in xenograft models in nude
mice [26,27,28,29,30,31,32]. Therefore, reactivation of FOXO
based on its tumor suppressor properties is considered as a very
attractive anti-cancer strategy. Since FOXO proteins were
reported to be critical mediators of apoptosis induced by
anticancer drugs, we postulated that FOXO expression or
transcriptional activity could be important event in mediating
the effects of resveratrol.
The objectives of our study were to examine the effects PI3K/
AKT pathway on the regulation of FOXO transcription factors
and their target gene products, and assess whether PI3K/AKT/
FOXO pathway regulates anti-proliferative effects of resveratrol in
prostate cancer cells. Our data demonstrated that inhibition of
PI3K/AKT pathway enhanced FOXO DNA-binding and
transcriptional activity, resulting in the regulation of its gene
products (TRAIL, DR4, DR5, Bim, p27
/KIP1 and cyclin D1).
Inhibition of PI3K/AKT pathway or overexpression of FKHR,
FKHRL1 and AFX enhanced resveratrol-induced FOXO tran-
scriptional activity. In contrast, inhibition of FKHR, FKHRL1 or
AFX blocked resveratrol-induced expression of TRAIL, DR4,
DR5, Bim and p27, and inhibited the expression of cyclin D1.
These data suggest that resveratrol induces apoptosis and growth
arrest through activation of FOXO transcription factors, and
inhibition of PI3K/AKT pathway activates FOXO transcription
factors and further enhances antiproliferative and proapoptotic
effects of resveratrol.
Results
Inhibition of PI3K/AKT pathway enhances resveratrol-
induced apoptosis in prostate cancer cells
We first examined the effects of pharmacological inhibition of
AKT by LY294002, Wortmannin or AKT inhibitor on resvera-
trol-induced apoptosis in LNCaP cells (Fig. 1A). Resveratrol
induced apoptosis in LNCaP cells. Similarly, LY294002, Wort-
mannin or AKT inhibitor slightly but significantly induced
apoptosis. Pretreatment of LNCaP cells with LY294002, Wort-
mannin or AKT inhibitor significantly enhanced resveratrol-
induced apoptosis at 48 h. These data suggest that inhibition of
PI3K/AKT activity by pharmacological approach enhanced
resveratrol-induced apoptosis.
The tumor suppressor gene PTEN is quite often inactivated in
human prostate cancers. The inactivation of PTEN can cause
constitutive phosphorylation and activation of AKT, leading to
enhanced cell growth and tumor progression. Since LNCaP cells
express constitutively active AKT, we sought to examine the role
of PI3K/AKT pathway on resveratrol-induced apoptosis. LNCaP
cells were transfected with empty vector or plasmid expressing wild
type PTEN, PTEN-G129E, or PTEN-G129R and incubated in
the presence or absence of resveratrol (Fig. 1B). Resveratrol
induced apoptosis in LNCaP cells transfected with empty vector.
Transfection of LNCaP cells with wild type PTEN significantly
enhanced resveratrol-induced apoptosis. Overexpression of
PTEN-G129E or PTEN-G129R in LNCaP cells significantly
inhibited resveratrol induced apoptosis than those transfected with
wild type PTEN. These data suggest that inhibition of AKT
activity by overexpression of PTEN enhances apoptosis-inducing
potential of resveratrol.
Since overexpression of PTEN enhances resveratrol-induced
apoptosis, we regulated AKT expression by wild type AKT (WT-
AKT), constitutively active AKT (CA-AKT) and dominant
negative AKT (DN-AKT). LNCaP cells were transiently trans-
fected with empty vector, WT-AKT, CA-AKT or DN-AKT and
treated with or without resveratrol (20 mM). Transfection of
LNCaP cells with empty vector, WT-AKT or CA-AKT had no
effect on apoptosis (Fig. 1C). Resveratrol induced apoptosis in
empty vector transfected cells. Overexpression of WT-AKT or
CA-AKT in LNCaP cells inhibited resveratrol-induced apoptosis.
Overexpression of DN-AKT alone significantly induced apoptosis.
Interestingly, overexpression of DN-AKT enhanced resveratrol-
induced apoptosis. Overall, these data suggest that inhibition of
PI3K/AKT pathway by genetic and pharmacological means
enhance resveratrol-induced apoptosis in prostate cancer cells.
Resveratrol inhibits phosphorylation of PI3K and AKT
Since PI3K/AKT pathway inhibits resveratrol-induced apop-
tosis, we sought to examine the effects of resveratrol on the
phosphorylation of PI3K and AKT (Fig. 1D). LNCaP cells were
treated with resveratrol and phosphorylation of PI3K and AKT
was examined by the Western blot analysis. Resveratrol inhibited
the phosphorylation of PI3K and AKT in a time dependent
manner. The phosphorylation of these kinases was abolished at
48 h. Resveratrol had no effect on the expression of total AKT.
Since mTOR is a down-stream of AKT, we next sought to
examine whether resveratrol also regulates phosphorylation of
mTOR. As shown in Fig. 1D, resveratrol inhibited the
phosphorylation of mTOR. These data suggest that resveratrol
can inhibit the phosphorylation of both PI3K/AKT and mTOR
proteins, and thus play a major role in mediating anti-apoptotic
effects of resveratrol.
Resveratrol Activates FOXO Transcription Factors
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FKHRL1 and AFX, but inhibits the phosphorylation of
FOXO proteins
PI3K/AKT pathway has been shown to regulate the
phosphorylation of FOXO proteins [33]. We therefore measured
the expression of FOXO genes by RT-PCR, and phosphoryla-
tion of FOXO proteins by Western blot analysis. Resveratrol had
no effect on the expression of FKHR, FKHRL1 and AFX as
measured by RT-PCR (Fig. 2A). We next sought to examine
whether resveratrol regulates phosphorylation of FOXO pro-
teins. As shown in Fig. 2B, resveratrol inhibited the phosphor-
ylation of FKHR, FKHRL1 and AFX. These data suggest that
resveratrol can inhibit the phosphorylation of FOXO proteins,
which are down stream of AKT, and dephosphorylation of
FOXO by resveratrol may result in its activation through nuclear
translocation.
Resveratrol enhances translocation of wild type and
mutant FKHR to nucleus and enhances FOXO-DNA
interaction
We next examined the nuclear translocation of FKHR by
resveratrol using wild type and mutant GFP-FKHR constructs.
LNCaP cells were transfected with either GFP-FKHR or GFP-
FKHR-TM (triple mutant) and treated with resveratrol for 24 h
(Fig. 2C). Translocation of wild type and phosphorylation deficient
mutant FKHR was observed by fluorescence microscopy.
Resveratrol induced the nuclear translocation of both wild type
and mutant FKHR. However, the nuclear translocation of
FKHR-TM was much higher than wild type FKHR.
We next examined the FOXO-DNA interaction by electropho-
retic mobility shift assay (EMSA). An electrophoretic mobility shift
assay (EMSA) is a common affinity electrophoresis technique used
to study protein-DNA interaction. Treatment of LNCaP cells with
Figure 1. Inhibition of PI3K/AKT pathway enhances apoptosis-inducing potential of resveratrol. (A), LNCaP cells were pretreated with
LY294002 (1 mM), Wortmannin (1 mM) or AKT inhibitor (100 nM) for 2 h, followed by treatment with resveratrol (20 mM) for 48 h. At the end of
incubation period, cells were harvested and apoptosis was measured by TUNEL assay. Data represent mean 6 SE. *, # and ** = significantly different
from respective control (P,0.05). (B), LNCaP cells were transiently transfected with empty vector, PTEN-WT, PTEN-G129E or PTEN-G129R. The culture
medium was changed and cells were treated with or without resveratrol (20 mM) for 48 h, and apoptosis was measured by TUNEL assay. Data
represent mean 6 SE. *, **, % and $ = significantly different from respective control (P,0.05). (C), LNCaP cells were transiently transfected with
empty vector, WT-AKT, CA-AKT or DN-AKT. The culture medium was changed and cells were treated with or without resveratrol (20 mM) for 48 h, and
apoptosis was measured by TUNEL assay. Data represent mean 6 SE. *, **, # and % = significantly different from respective control (P,0.05). (D),
Effects of resveratrol on the expression of PI3K, AKT and mTOR pathway. LNCaP cells were treated with resveratrol (20 mM) for various time points.
Western blots were performed with anti-phospho-PI3K, phospho-AKT, anti-AKT and phospho-mTOR antibodies. b-Actin was used as a loading
control. The data are representative of three experiments.
doi:10.1371/journal.pone.0015288.g001
Resveratrol Activates FOXO Transcription Factors
PLoS ONE | www.plosone.org 3 December 2010 | Volume 5 | Issue 12 | e15288resveratrol resulted in enhanced FOXO-DNA interaction (Fig. 2D,
left panel). The incubation of cold probe with the nuclear extract
resulted in reduced FOXO-DNA binding activity. By comparison,
the incubation of non-specific cold SP1 probe had no effect on
FOXO-DNA binding. The combination of LY294002 or AKT
inhibitor with resveratrol slightly enhanced the FOXO-DNA
binding activity, than single agent alone (Fig. 2D, right panel).
Overall, these data suggest that resveratrol can enhance FOXO
nuclear translocation and DNA binding activity.
Inhibition of PI3K/AKT pathway and phosphorylation
deficient mutants of FOXO proteins enhance resveratrol-
induced FOXO transcriptional activity
We next examined whether inhibition of PI3K/AKT pathway
enhances resveratrol-induced FOXO transcriptional activity in a
luciferase reporter gene assay which measures FOXO function
(Fig. 3A–C). We have first taken a pharmacological approach to
inhibit PI3K/AKT activity by using Wortmannin, LY-294002,
and AKT inhibitor IV. Wortmannin, LY-294002, AKT inhibitor
IV and resveratrol alone induced FOXO transcriptional activity.
Furthermore, the combination treatment of Wortmannin, LY-
294002, or AKT inhibitor IV with resveratrol further enhanced
FOXO activity. These data suggest that inhibition of PI3K/AKT
pathway act synergistically with resveratrol to induce FOXO
transcriptional activity.
We next examined the effects of AKT on resveratrol-induced
FOXO activity in LNCaP cells (Fig. 3B). The AKT activity was
regulated by wild type AKT (WT-AKT), constitutively active
AKT (CA-AKT) and dominant negative AKT (DN-AKT).
LNCaP cells were transiently transfected with empty vector,
Figure 2. Regulation of FOXO by resveratrol. (A), Effects of resveratrol on the expression of FKHR, FKHRL1 and AFX. LNCaP cells were treated
with resveratrol (10 or 20 mM) for 6, 12 or 24 h. Total RNA was isolated and RT-PCR analysis was performed to measure the expression of FKHR,
FKHRL1 and AFX. (B), Effects of resveratrol on the phosphorylation of FOXO proteins. LNCaP cells were treated with resveratrol (20 mM) for 0–48 h,
and the Western blot analyses were performed to measure the expression of phospho-FKHR, phospho-FKHRL1 and phosphor-AFX. b-Actin was used
as a loading control. (C), Resveratrol induces translocation of FKHR to nucleus. LNCaP cells were seeded in chambered slides and transfected with
GFP-FKHR or GFP-FKHR-TM (phosphorylation deficient triple mutant). The culture medium was changed and cells were treated with or without
resveratrol (20 mM) for 24 h. Cells were fixed, permeabilized, and stained with DAPI and visualized under a fluorescence microscope. green color =
FKHR, red color = nucleus (for clarity the color of nucleus was changed from blue to red), yellow = colocalization of FKHR to nucleus. (D), Left panel,
LNCaP cells were treated with resveratrol (20 mM) for various time points (0–24 h). Nuclear extracts were prepared and the gelshift experiment was
performed as described in Materials and Methods. Lane 1= probe only, lanes 2–9= resveratrol treated samples, lane 10= cold probe (506), and lane
11= cold SP1 probe. The data are representative of three experiments. Right panel, LNCaP cells were untreated or treated with resveratrol (20 mM) in
the presence or absence of LY (1 mM) or AKT inhibitor (100 nM) for 24 h. Nuclear extracts were prepared and the gelshift experiment was performed
as described in Materials and Methods. Lane 1= probe only, lane 2= cold probe (506), lane 3= cold SP1, lane 4= control, lane 5= resveratrol, lane
6= LY, lane 7= AKT inhibitor, lane 8= resveratrol plus LY, lane 9= resveratrol + AKT inhibitor. The data are representative of three experiments.
doi:10.1371/journal.pone.0015288.g002
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resveratrol (20 mM). Transfection of LNCaP cells with empty
vector, WT-AKT, or CA-AKT had no effect on FOXO
transcriptional activity. By comparison, transfection of cells with
DN-AKT induced significant FOXO transcriptional activity.
Resveratrol induced FOXO transcriptional activity in cells
transfected with empty vector. Overexpression of WT-AKT or
CA-AKT in LNCaP cells inhibited resveratrol-induced FOXO
transcriptional activity. Interestingly, overexpression of DN-AKT
enhanced resveratrol-induced FOXO transcriptional activity.
Overall, these data suggest that inhibition of AKT activity by
genetic approach enhances resveratrol-induced FOXO transcrip-
tional activity in prostate cancer cells.
Since LNCaP cells express mutant PTEN resulting in
constitutive activation of AKT, we sought to examine the role of
PTEN on resveratrol-induced FOXO transcriptional activity
(Fig. 3C). LNCaP cells were transfected with empty vector or
plasmid expressing wild type PTEN, PTEN-G129E, or PTEN-
G129R and treated with or without resveratrol. PTEN-WT
slightly induced FOXO transcriptional activity. Resveratrol
Figure 3. Inhibition of PI3K/AKT pathway or overexpression of phosphorylation deficient mutants of FOXO enhanced resveratrol-
induced FOXO transcriptional activity. (A), Pharmacological inhibition of PI3K/AKT pathway enhanced resveratrol-induced FOXO activity in
LNCaP cells. LNCaP cells were transiently transfected with 6X DBE-luciferase and pRL-TK plasmids for 24 h as we described elsewhere. After
transfection, cells were pretreated with Wortmannin (10 mM), LY-294002 (10 mM) or AKT inhibitor IV (1 mM) for 2 h, followed by treatment with or
without resveratrol (20 mM) for 24 h. Cells were harvested for firefly/Renilla luciferase assays using the Dual-Luciferase Reporter Assay System
(Promega). Luciferase counts were normalized using Renilla luciferase transfection control. Data represent the mean 6 S.D. *, #, ** = significantly
different from control, P,0.05. (B), Overexpression of dominant negative AKT enhanced resveratrol-induced FOXO activity. LNCaP cells were
transiently transfected with 6X DBE-luciferase plus pRL-TK plasmids with WT-AKT, CA-AKT or DN-AKT for 24 h. After transfection, cells were pretreated
with resveratrol (20 mM) for 24 h. Cells were harvested for firefly/Renilla luciferase assays using the Dual-Luciferase Reporter Assay System (Promega).
Luciferase counts were normalized using Renilla luciferase transfection control. Data represent the mean 6 S.D. *, # and ** = significantly different
from control, P,0.05. (C), Regulation of resveratrol-induced FOXO activity by wild type or mutant PTEN. LNCaP cells were transiently transfected with
6X DBE-luciferase plus pRL-TK plasmids with PTEN-WT, PTEN-G129E or PTEN-G129R for 24 h. After transfection, cells were pretreated with resveratrol
(20 mM) for 24 h. Cells were harvested for firefly/Renilla luciferase assays using the Dual-Luciferase Reporter Assay System (Promega). Luciferase
counts were normalized using Renilla luciferase transfection control. Data represent the mean 6 S.D. *, &, $ and ** = significantly different from
control, P,0.05. (D), Phosphorylation deficient mutants of FOXO enhance resveratrol-induced FOXO transcriptional activity. LNCaP cells were
transiently transfected with empty vector or constructs encoding FOXO1-TM, FOXO3a-TM, or FOXO4-TM together with 6X DBE-luciferase and pRL-TK
plasmids for 24 h. After transfection, cells were washed, treated with resveratrol (20 mM) for 24 h, and harvested for firefly/Renilla luciferase assays
using the Dual-Luciferase Reporter Assay System (Promega). Luciferase counts were normalized using Renilla luciferase transfection control. Data
represent the mean 6 S.D. * and ** = significantly different from control, P,0.05.
doi:10.1371/journal.pone.0015288.g003
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with empty vector. Transfection of LNCaP cells with wild type
PTEN or PTEN-G129E significantly enhanced resveratrol-
induced FOXO transcriptional activity. By comparison, overex-
pression of PTEN-G129R in LNCaP cells had FOXO transcrip-
tional activity similar to that of resveratrol treated LNCaP/empty
vector cells. These data suggest that inhibition of AKT activity by
overexpression of PTEN enhances FOXO transcriptional activity.
We next examined whether resveratrol induces transcriptional
activation of FOXO in the presence or absence of FOXO1-TM,
FOXO3a-TM, or FOXO4-TM (phosphorylation deficient triple
mutant) (Fig. 3D). LNCaP cells were transfected with p6xDBE-
luciferase reporter construct in the presence or absence of plasmids
expressing FOXO1-TM, FOXO3a-TM, or FOXO4-TM. After
transfection, cells were treated with resveratrol for 24 h, and
luciferase activity was measured. Transfection of cells with
plasmids expressing FOXO1-TM, FOXO3a-TM, or FOXO4-
TM induced FOXO transcriptional activity compared with the
empty vector (control). Resveratrol-induced FOXO transcription-
al activity was further enhanced in the presence of phosphoryla-
tion deficient mutants of FOXO1, FOXO3a, and FOXO4. These
data indicate that activation of FOXO transcription factors further
enhances resveratrol-induced FOXO transcriptional activity.
Inhibition of PI3K/AKT pathway regulates Bim, p27
/Kip1,
cyclin D1, TRAIL, TRAIL-R1/DR4 and TRAIL-R2/DR5
We next examined the effect of inhibiting PI3K/AKT pathway
on the expression of Bim, p27
/Kip1, cyclin D1, TRAIL, TRAIL-
R1/DR4 and TRAIL-R2/DR5. These genes are direct targets of
FOXO transcription factor. LNCaP cells were pretreated with
LY-294002 or AKT inhibitor IV followed by treatment with
resveratrol for 24 h, and the expression of Bim, p27, cyclin D1,
TRAIL, DR4 and DR5 was measured by Western blotting (Fig. 4).
LY-294002 and AKT inhibitor IV induced the expression of Bim,
p27
/Kip1, TRAIL, DR4 and DR5, and inhibited the expression of
cyclin D1. Treatment of cell with resveratrol further enhanced the
effects of LY-294002 or AKT inhibitor IV on the expression of
Bim, TRAIL, DR4 and DR5. However, the combination of LY-
294002 or AKT inhibitor IV with resveratrol had no further effect
on the expression of p27
/KIP1 and cyclin D1. These data suggest
that inhibition of PI3K/AKT pathway can regulate the expression
of Bim, p27
/Kip1, cyclin D1, TRAIL, DR4 and DR5, which are
transcriptional targets of FOXO. Resverarol may also regulate the
expression of these FOXO transcriptional targets.
Inhibition of FOXO expression by shRNA inhibits the
antiproliferative effects of resveratrol and blocked
resveratrol-induced caspase-3 activity and apoptosis
If resveratrol induces apoptosis by activating FOXO transcrip-
tion factor, the inhibition of FOXO proteins should block the anti-
proliferative effects of resveratrol. LNCaP cells were transfected
with shRNA expressing FKHR, FKHRL1 or AFX and treated
with resveratrol (Fig. 5). Resveratrol induced apoptosis in LNCaP/
FKHR scrambled, LNCaP/FKHRL1 scrambled and LNCaP/
AFX scrambled cells in a dose-dependent manner (Fig. 5A).
Inhibition of FKHR, FKHRL1 or AFX by shRNA blocked anti-
proliferative effects of resveratrol. These data suggest that
resveratrol inhibits cell viability through regulation of FOXO
transcription factors.
We next sought to examine whether inhibition of FOXO
expression effectresveratrol-induced caspase-3 activity and apoptosis
(Fig.5B and C). Resveratrol induced caspase-3activityandapoptosis
inLNCaP/scrambled cells. Pretreatment of LNCaP/scrambled cells
with NAC inhibited resveratrol-induced caspase-3 activity and
apoptosis. Inhibition of FOXO expression by shRNA inhibited
resveratrol induced caspase-3 activity and apoptosis. Interestingly,
pretreatment of LNCaP/FOXO shRNA cells with NAC blocked
resveratrol-induced caspase-3 activity and apoptosis. These data
suggest that resveratrol induced caspase-3 activity and apoptosis
through generation of ROS, and inhibition of FOXO (FKHR,
FKHRL1 and AFX) inhibits caspase-3 activity and apoptosis.
Regulation of Bim, TRAIL, DR4, DR5, p27
/Kip1 and cyclin
D1 by FOXO genes (FKHR, FKHRL1 and AFX)
FOXO transcription factors have been shown to regulate
apoptosis and cell cycle-related genes [14,34]. Since resveratrol
regulated the expression of Bim, TRAIL, DR4, DR5, p27
/Kip1
and cyclin D1, we sought to examine whether these effects of
resveratrol are mediated through FOXO transcription factors
which were inhibited by shRNA (Fig. 6). Resveratrol induced the
expression of Bim (BimEL, BimL and BimS), TRAIL, DR4, DR5
and p27
/Kip1, and inhibited the expression of cyclin D1 in
LNCaP/scrambled cells. Inhibition of FKHR, FKHRL1 or AFX
by shRNA attenuated resveratrol-induced Bim, TRAIL, DR4,
DR5 and p27
/Kip1 expression. By comparison, inhibition of
FKHR, FKHRL1 or AFX by shRNA slightly attenuated the
inhibitory effects of resveratrol on cyclin D1 expression. These
data suggest that resveratrol can regulate apoptosis (Bim, TRAIL,
DR4, and DR5) and cell cycle-related genes (p27
/Kip1, and cyclin
D1) through FOXO transcription factors. Interestingly, induction
of TRAIL and its receptors DR4 and DR5 by resveratrol will
result in activation of extrinsic pathway of apoptosis.
Figure 4. Effects of PI3K/AKT pathway and resveratrol on the
expression of FOXO target genes. LNCaP cells were pretreated with
LY294002 (10 mM) or AKT inhibitor (AKT-I, 1 mM) for 2 h and treated
with or without resveratrol (20 mM) for 48 h. Cells were harvested to
measure the expression of Bim, p27
/KIP1, cyclin D1, TRAIL, DR4 and DR5
by theWestern blot analysis. b-actin was used as a loading control.
doi:10.1371/journal.pone.0015288.g004
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In the present study, we have shown that resveratrol induced
apoptosis in prostate cancer cells through inhibition of PI3K/AKT
and mTOR pathway, and activation of FOXO transcription
factors. Furthermore, downregulation of PI3K/AKT pathway
increased resveratrol-induced apoptosis. Inhibition of FOXO
transcription factors by shRNA blocked resveratrol-induced
upregulation of Bim, TRAIL, DR4, DR5, p27
/Kip1 and apoptosis,
and resveratrol-induced inhibition of cyclin D1. Our data suggest
that resveratrol induces cell cycle arrest and apoptosis through
regulation of FOXO transcription factors in prostate cancer cells.
Overall, these properties of resveratrol strongly suggest that it
could be used as a cancer chemopreventive agent.
FOXO transcription factors are tumor suppressors that are
inactivated in the majority of human cancers, owing to the
overactivation of the PI3K/AKT pathway [35,36,37]. FOXO
proteins can regulate a variety of genes that influence cell
proliferation, survival, metabolism and response to stress [38].
The FOXOs are regulated by synthesis, phosphorylation,
acetylation and ubiquitination at three different levels: subcellular
localization, stability and transcriptional activity [39]. Upon the
activation of PI3K/AKT signaling, FOXOs undergo AKT-
mediated phosphorylation, which promotes binding to 14-3-3,
nuclear export through CRM1 and cytoplasmic sequestration.
Under stress conditions or in the absence of growth or survival
factors, when the PI3K/AKT pathway is inhibited, FOXO
proteins translocate to the cell nucleus, where their transcriptional
Figure 5. Effects of FOXO transcription factors on the regulation of antiproliferative and proapoptotic effects of resveratrol. (A),
Inhibition of FOXO transcription factor by shRNA blocks anti-proliferative effects of resveratrol. LNCaP cells were transiently transfected with plasmids
expressing FKHR shRNA, FKHRL1 shRNA, AFX shRNA or respective scrambled control and treated with resveratrol (20 mM) for 48 h, and cell viability
was measured. (B), Inhibition of FOXO transcription factors or ROS (reactive oxygen species) by NAC blocks resveratrol-induced apoptosis. LNCaP cells
were transfected with a mixture of plasmids expressing FKHR shRNA, FKHRL1 shRNA plus AFX shRNA or scrambled control. After transfection, the
culture medium was changed and cells were pretreated with NAC for 2 h, and treated with resveratrol (20 mM) for 48 h. At the end of incubation
period, the apoptosis was measured by TUNEL assay. (C), Inhibition of FOXO transcription factors or ROS by NAC blocks resveratrol-induced caspase-3
activity. LNCaP cells were transfected with a mixture of plasmids expressing FKHR shRNA, FKHRL1 shRNA plus AFX shRNA or scrambled control. After
transfection, the culture medium was changed and cells were pretreated with NAC for 2 h, and treated with resveratrol (20 mM) for 48 h. At the end
of incubation period, the caspase-3 activity was measured as per manufacturer instructions.
doi:10.1371/journal.pone.0015288.g005
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PI3K/AKT pathway enhanced FOXO-DNA binding and
transcriptional activity. Furthermore, phosphorylation deficient
mutant of FOXO enhanced resveratrol-induced FOXO tran-
scriptional activity and apoptosis. Post-translational modification
of FOXO proteins is an important mechanism that regulates the
ability of different transcription factors to activate distinct gene
sets, involved in cell cycle inhibition [40], apoptosis [41], defense
against oxidative stress and DNA repair [36,42,43]. The enhanced
DNA binding activity also serves to limit the availability of FOXO
proteins for phosphorylation by AKT [44]. So, rather than
enhancing dephosphorylation of phospho-FOXO proteins, resver-
atrol may be simply inhibiting the rephosphorylation of FOXO
proteins after they have been dephosphorylated. Thus, resveratrol
treatment inhibits the accumulation of phospho-FOXO, either by
inhibiting the phosphorylation of FOXO proteins in the nucleus,
or by promoting the dephosphorylation of phosphorylated form of
FOXO proteins in the cytoplasm.
ROS are thought to play multiple roles including tumor
initiation, progression and maintenance, and ROS production is
highly increased in cancer cells (Szatrowski and Nathan, 1991;
Burdon, 1995). High levels of ROS under stress conditions have
been shown to inhibit phosphorylation and acetylation of FOXO
proteins, resulting in enhanced FOXO-DNA binding activity. In
the cell, ROS levels can be sensed by virtue of stimulatory and
inhibitory oxidative modification of cysteine residues within
proteins that control various signaling cascades. Recently it was
shown that cysteines in FOXO can also act as sensors of the local
redox state. The cysteine-dependent redox switch can regulate
ROS signaling pathway upstream of FOXO. Furthermore,
FOXO can also control ROS levels by transcriptional regulation
of a multilayered antioxidant system. Thus, cysteine based redox
signaling to FOXO could play a role in fine-tuning the optimal
cellular response to ROS to control organismal lifespan. In our
study, phosphorylation deficient mutants of FOXO enhanced
resveratrol-induced FOXO transcriptional activity and apoptosis.
This may be because resveratrol induces ROS leading to induction
of SIRT1 which in turn causes deacetylation of FOXO proteins
and enhances DNA binding activity [44]. ROS-induced cell death
was suppressed by co-transfection of a FOXO3a mutant that lacks
the activation-domain of transcription, transactivation of pro-
apoptotic genes by FOXO was necessary to cause ROS-induced
apoptosis [45]. In fact, expression of several pro-apoptotic genes,
such as Bim and Bcl-6 was induced in H2O2-stimulated cells, and
was blocked by co-transfection of dominant-negative type
FOXO3a mutant. These findings indicate that FOXO is a key
regulator of ROS-induced apoptosis in mammalian cells.
FOXO transcription factors play important roles in regulation
of cell cycle and apoptosis [46,47]. In the present study, it appears
that FKHR, FKHRL1 and AFX play overlapping roles in
regulation of cell cycle and apoptosis-related genes. The inhibition
of FKHR, FKHRL1 or AFX by shRNA attenuated resveratrol-
induced expression of Bim, TRAIL, DR4, DR5 and p27
/kip1 and
apoptosis. Furthermore, the inhibition of FKHR, FKHRL1 or
AFX by shRNA blocked the inhibitory effects of resveratrol on
cyclin D1. Similar to our studies, FOXO silencing has been shown
to decrease expression levels of Bim, TRAIL, FasL, p27
/Kip1,
which are FOXO target genes controlling cell cycle and apoptosis
[40,48,49,50,51,52,53]. We have recently demonstrated that
inhibition of PI3K/AKT and MEK/ERK pathways act synergis-
tically to regulate antiangiogenic effects of EGCG, resveratrol and
sulforaphane through activation of FOXO transcription factors
Figure 6. FOXO transcription factors mediate the expression of cell cycle and apoptosis-related genes. (A), LNCaP cells were transfected
with plasmids expressing FKHR shRNA or scrambled control. After transfection, the culture medium was changed and cells were treated with
resveratrol (0–20 mM) for 48 h. At the end of incubation period, cells were harvested to measure the expression of Bim, TRAIL, DR4, DR5, p27 and
cyclin D1 by the Western blot analysis. b-actin was used as a loading control. (B), LNCaP cells were transfected with plasmids expressing FKHRL1
shRNA or scrambled control. After transfection, the culture medium was changed and cells were treated with resveratrol (0–20 mM) for 48 h. At the
end of incubation period, cells were harvested to measure the expression of Bim, TRAIL, DR4, DR5, p27 and cyclin D1 by the Western blot analysis. b-
actin was used as a loading control. (C), LNCaP cells were transfected with plasmids expressing AFX shRNA or scrambled control. After transfection,
the culture medium was changed and cells were treated with resveratrol (0–20 mM) for 48 h. At the end of incubation period, cells were harvested to
measure the expression of Bim, TRAIL, DR4, DR5, p27 and cyclin D1 by the Western blot analysis. b-actin was used as a loading control.
doi:10.1371/journal.pone.0015288.g006
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inhibition of these PI3K/AKT and MEK/ERK pathways may
have physiological significance in management of diabetic
retinopathy, psoriasis, cardiovascular diseases, rheumatoid arthri-
tis and cancer.
In summary, our study demonstrate that dephosphorylation of
FOXO may stabilize and enhance FOXO’s DNA binding and
transcriptional activity. Our findings demonstrate that resveratrol
regulates the expression of FOXO’s target genes such as Bim,
TRAIL, DR4, DR5, cyclin D1 and p27
/KIP1. In addition to
regulation of FOXO through dephosphorylation, resveratrol may
also regulate cell survival and/or apoptosis through global
modulation of gene expression via deacetylation of FOXO
transcription factor. Further studies are needed to assess the
physiological significance of phosphorylation vs acetylation of
FOXO proteins. A thorough understanding of the mechanisms of
resveratrol may lead to discovery and development of novel
therapeutic molecules for the treatment and prevention of human
diseases.
Methods
Reagents
Antibodies against Bim, TRAIL, DR4, DR5, p27
/KIP1, cyclin
D1 and b-actin were purchased from Santa Cruz Biotechnology
Inc. (Santa Cruz, CA). Enhanced chemiluminescence (ECL)
Western blot detection reagents were from Amersham Life
Sciences Inc. (Arlington Heights, IL). Terminal Deoxynucleotidyl
Transferase Biotin-dUTP Nick End Labeling (TUNEL) assay kit
and caspase-3 activity kit were purchased from EMD Biosciences
(Gibbstown, NJ). Resveratrol was purchased from LKT Labora-
tories, Inc. (St. Paul, MN). All other chemicals used were of
analytical grade and were purchased from Fisher Scientific
(Suwanee, GA) and Sigma-Aldrich (St. Louis, MO).
Cell Culture
LNCaP cells were obtained from the American Type Culture
Collection (Manassas, VA) and cultured in RPMI 1640 supple-
mented with 10% fetal bovine serum (FBS) and 1% antibiotic-
antimycotic at 37uC in a humidified atmosphere of 95% air and
5% CO2.
Construction of FOXO shRNA vector
Expression plasmids for silencing of FKHR, FKHRL1 and
AFX were constructed using psiRNA-DUO-GFP-Zeo vector (In
vivoGen, San Diego, California).
Transient Transfection
Cells were plated in 60-mm dishes in RPMI 1640 containing
10% FBS and 1% penicillin-streptomycin mixture at a density of
1610
6 cells/dish. The next day transfections were performed
using LipofectAMINE (Invitrogen Life Technologies, Carlsbad,
CA). Cells were transfected with expression constructs encoding
wild type PTEN (pSG5L-HA-PTENwt), mutant PTEN (pSG5L-
HA-PTEN-G 129E and pSGL5-HA-PTEN-G 129R), wild type-
AKT (pUSE-WT-AKT), constitutively active-AKT (pUSE-CA-
AKT), dominant negative-AKT (pUSE-DN-AKT), or the corre-
sponding empty vectors (pSG5L or pUSE) in the presence of an
expression vector pCMV-LacZ (Invitrogen Life Technologies)
expressing b-galactosidase. For each transfection, 2 mg of DNA
was diluted into 50 ml of medium without serum. After the
addition of 3 ml of LipofectAMINE into 50 ml Opti-MEM
medium, the transfection mixture was incubated for 10 min at
room temperature. Cells were washed with serum-free medium,
the transfection mixture was added, and cultures were incubated
for 24 hrs in the incubator. The next day, culture medium was
replaced with fresh RPMI 1640 containing 10% FBS and 1%
penicillin-streptomycin mixture and resveratrol was added for
desired times for the measurement of apoptosis and protein
expression.
Measurement of Apoptosis
Cells were treated with resveratrol and apoptosis was measured
by TUNEL assay as per manufacturer instructions.
Caspase-3 Assay
Cells (3610
4 per well) were seeded in a 96-well plate with 200 ml
culture medium. Approximately 16 h later, cells were treated with
various doses of resveratrol to induce apoptosis. Casapse-3 activity
was measured as per manufacturer’s instructions (EMD Biosci-
ences) with a fluorometer.
Western Blot Analysis
Cells were treated with resveratrol for various time points and
lysed in the RIPA buffer containing 1 X protease inhibitor
cocktail. Protein concentrations were determined using the Bio-
Rad Protein Assay (Bio-Rad, Hercules, CA). Cell lysates
containing 40 mg of protein were analyzed using 12.5%
SDSPAGE. Transferred membranes were blocked using 5% skim
milk and incubated overnight with primary antibodies followed by
secondary antibodies conjugated with horseradish peroxidase at
1:5,000 dilution in TBS-Tween 20 for 1 hour at room temper-
ature. Membranes were developed using ECL Substrate. Protein
bands were visualized on X-ray film using an enhanced
chemiluminescence system.
Immunocytochemistry
Cells were grown on fibronectin-coated coverslips (Beckton
Dickinson, Bedford, MA), washed in PBS, and fixed for 15 min in
4% paraformaldehyde. Cells were permeabilized in 0.1% Triton
X-100, washed and blocked in 10% normal goat serum. After
blocking, cells were incubated with primary antibody (1:100) for
18 h at 4uC, washed with PBS and incubated with fluorescently
labeled secondary antibody (1:200) along with DAPI (1 mg/ml) for
1 h at room temperature. Finally, coverslips were washed and
mounted using Vectashield (Vector Laboratories, Burlington, CA).
Isotype-specific negative controls were included with each staining.
Stained cells were mounted and visualized under a fluorescent
microscope.
Luciferase Assay
LNCaP cells were transfected with empty vector, FOXO1-TM,
FOXO3a-TM or FOXO4-TM along with reporter plasmids,
p6xDBE-luc and pRL-TK [55]. The FOXO expression vectors
(wild type and phosphorylation deficient mutants) and FOXO-
luciferase constructs have been described elsewhere [55,56]. After
24 h, transfection medium was replaced with culture medium and
cells were treated with resveratrol (0–20 mM). After incubation of
24 h, the relative luciferase activity, i.e. firefly enzyme activity
divided by that of the Renilla enzyme, was determined using Dual
Luciferase Reporter Assay System (Promega, Madison, WI)
according to the manufacturer’s protocol.
RT-PCR
Total RNA was extracted using the RNeasy Mini Kit (Qiagen,
Valencia, CA) and first strand cDNA was synthesized with the
Omniscript RT kit (Qiagen), using 1 mg of RNA per 20 ml reaction
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for FKHR, FKHRL1, AFX and GAPDH.
Electrophorectic mobility shift assay (EMSA)
FOXO probes were end-labeled with [c-
32P] dATP by
incubating oligodeoxyribonucleotide strands with 56 reaction
buffer and 10 U T4 polynucleotide kinase for 1 h at 37uC. Then
labeled oligonucleotides were allowed to anneal at room
temperature for 10 min and 20 mg protein from each sample
was used in 25 ml binding reactions, which consisted of 1 mg poly
dI-dC, in 56binding buffer (50 mM Tris HCl; pH 8.0, 750 mM
KCl, 2.5 mM EDTA, 0.5% Triton-X 100, 62.5% glycerol (v/v)
and 1 mM DTT). To determine specificity of DNA binding,
samples were incubated with or without 20 ng of unlabeled
competitor DNA for 10 min at room temperature. Then 0.1 ng of
labeled probe was added and samples were further incubated for
20 min at room temperature. Samples were separated on a 5%
non-denaturing polyacrylamide gel in 0.5% TBE and visualized
by autoradiography.
Statistical Analysis
The mean and SD were calculated for each experimental
group. Differences between groups were analyzed by one or two
way ANOVA using PRISM statistical analysis software (GrafPad
Software, Inc., San Diego, CA). Significant differences among
groups were calculated at P,0.05.
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